Think

Search This Blog

New A.L.S. Treatment Lacks Evidence of Benefit, F.D.A. Panel Finds

March 30, 2022

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

BY PAM BELLUCK | NYTimes Health | Disclosure

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

Comments

A new drug slashes deaths among patients with severe Covid, the drug’s developer claims.

BY RONI CARYN RABIN | NYTimes Health | Disclosure

Close to Half of American Adults Infected With Genital HPV, Study Finds

According to a survey published by the National Center for Health Statistics, more than 42 percent of Americans between the ages of 18 and 59 are infected with genital human papillomavirus (HPV). By NICHOLAS BAKALAR via NYT Health

Many U.S. virus cases go uncounted. Are there better ways to track the pandemic?

BY EMILY ANTHES | NYTimes Health | Disclosure

A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says

Results of a large clinical trial found the treatment did not work any better than a placebo. Pam Belluck | NYTimes Health | Disclosure

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy. Gina Kolata | NYTimes Health | Disclosure

Powered by Blogger

New A.L.S. Treatment Lacks Evidence of Benefit, F.D.A. Panel Finds

Comments

Post a Comment